Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(02): 6-10
DOI: 10.4103/0971-5851.51425
Original Article

Significance of haemostatic markers in ovarian carcinoma

S Sitalakshmi
Department of Clinical Pathology, St. John′s Medical College Hospital, Bangalore - 560034, India
,
Karuna Rameshkumar
Department of Clinical Pathology, St. John′s Medical College Hospital, Bangalore - 560034, India
,
Prema Damodar
Department of Clinical Pathology, St. John′s Medical College Hospital, Bangalore - 560034, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: Most cancer patients with metastatic disease have abnormal coagulation parameters. Although many abnormal blood coagulation tests have been reported in malignancies, there is little agreement regarding which tests are most useful to predict disease progression and hence this study was undertaken. Methods: In this prospective study, baseline and special coagulation tests were performed on 23 patients with ovarian adenocarcinoma. The baseline tests were PT, APTT, TT and platelet count. The special tests included factor VIII, factor IX and fibrinogen assay and semiquantitative measurement of D-dimer and FDP levels The cases were grouped into early and advanced disease groups. The results of the coagulation tests were analysed using suitable statistical methods. The results were compared between limited and advanced disease by chi square and Mann Whitney U test Results: The percentage of cases with increased D-dimer and fibrin degradation products (FDP) values were higher in the advanced disease compared to early disease. Two cases in stage IV had DIC. The PT, APTT, TT and platelet count did not show any statistically significant differences between the early and advanced disease groups. Factor VIII, factor IX and fibrinogen levels were not significantly different between two groups. Conclusion: Elevated D dimer& FDP are associated with advanced stage ovarian adenocarcinoma.



Publication History

Article published online:
02 March 2022

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 von Tempelhoff GF, Dietrich M, Niemann F et al Coagulation and thrombosis in patients with ovarian malignancy Thromb Haemost.1997;77(3):456-61.
  • 2 Dacie and Lewis Practical Haematology Ed Lewis SM, Bain BJ and I Bates I 9th ed 2001 Publ: Churchill Livingstone.
  • 3 Francis L. Haemostasis and cancer. Med Lab Sci 1989;46:331-346.
  • 4 Menczer J, Schejter E, Geva D et al Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol. 1998; 19 (1):82-4.
  • 5 Zeimet AG, Marth C, Mόller-Holzner E et al Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994;170(2):549-54.
  • 6 Wojtukiewiez MZ, Sierko E, Klement P et al. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3(5):371-384.
  • 7 Edwards RL, Fredrick RR, Martz TE et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602.
  • 8 Ikeda M, Furukawa H, Imamura H et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287-291.
  • 9 Rosen PJ. Bleeding problems in the cancer patients. Hematol Oncol Clin North Am 1992;6:1315-28.
  • 10 Khoo SK, Rylatt DB, Parson P et al. Serial D-dimer level in the assessment of tumour mass and clinical outcome in ovarian carcinoma. Gynecol Oncol 1988;29(2):188-98.
  • 11 Koh SC, Tham KF, Razvi K et al Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and anti thrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost. 2001;7(2):141-8.
  • 12 Koh SC, Khalil R, Lim FK et al The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost. 2006;12(1):3-8.
  • 13 Gadducci A, Marrai R, Baicchi U Measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer Anticancer Res. 1995;15(6B):2683- 6.